Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06643390 | A Study of MK-2225 in Healthy Participants (MK-2225-003) | PHASE1 | COMPLETED | 32 | — | — | Nov 21, 2023 | Jul 14, 2025 | Jul 29, 2025 | 2 | United States |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study/study treatment due to an AE will be reported.
| Arm | Type | Description |
|---|---|---|
| MK-2225 Panel A | EXPERIMENTAL | Participants receive MK-2225 Dose 1 subcutaneously (SQ) once every 2 weeks (Q2W) over the course of 8 weeks. |
| MK-2225 Panel B | EXPERIMENTAL | Participants receive MK-2225 Dose 2 SQ Q2W over the course of 8 weeks based on the safety and tolerability of the previous starting dose. |
| MK-2225 Panel C | EXPERIMENTAL | Participants receive MK-2225 Dose 3 SQ Q2W over the course of 8 weeks based on the safety and tolerability of the previous starting dose. |
| MK-2225 Panel D | EXPERIMENTAL | Participants receive MK-2225 Dose 4 SQ Q2W over the course of 8 weeks based on the safety and tolerability of the previous starting dose. |
| Placebo | PLACEBO_COMPARATOR | Participants receive placebo SQ Q2W over the MK-2225-matched time period. |
| Name | Type | Description |
|---|---|---|
| MK-2225 | DRUG | Subcutaneous administration |
| Placebo | OTHER | Subcutaneous administration |
Inclusion Criteria: The key inclusion criteria include but are not limited to the following: * Is in good health before randomization * Body Mass Index (BMI) ≤32 kg/m\^2, inclusive Exclusion Criteria: The key exclusion criteria include but are not limited to the following: * History of clinical...